Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Short-term Investments (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Short-term Investments for 3 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 61.31% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 61.31% year-over-year, with the annual reading at $6.0 million for FY2025, 61.31% down from the prior year.
  • Short-term Investments hit $6.0 million in Q4 2025 for Connect Biopharma Holdings, down from $16.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $36.3 million in Q1 2025 to a low of $6.0 million in Q4 2025.
  • Historically, Short-term Investments has averaged $19.7 million across 3 years, with a median of $16.2 million in 2024.
  • Biggest five-year swings in Short-term Investments: grew 22.63% in 2024 and later plummeted 61.31% in 2025.
  • Year by year, Short-term Investments stood at $12.6 million in 2023, then grew by 22.63% to $15.5 million in 2024, then tumbled by 61.31% to $6.0 million in 2025.
  • Business Quant data shows Short-term Investments for CNTB at $6.0 million in Q4 2025, $16.9 million in Q3 2025, and $31.1 million in Q2 2025.